Chemoradiotherapy

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

Retrieved on: 
Tuesday, April 9, 2024
PDT, Chemoradiotherapy, Head, Disease, Intelligence, Patient, Neoplasm, Health care, Cancer, AI, AACR, NEC, Curie Institute (Paris), Euronext Paris, Poster, Corporation, Neck, Vaccine

Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.

Key Points: 
  • Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.
  • These data are highlighted in the AACR press conference being held today and in a poster presentation which will take place tomorrow, April 10, at 9:00 a.m. PDT.
  • Key findings of the poster include:
    All 16 patients who received TG4050 are disease free after a median 18.6-month follow-up.
  • TG4050 is now starting to show a potential benefit for head and neck cancer patients at high risk of relapse.

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Retrieved on: 
Thursday, April 4, 2024
Toxicity, B cell, Conditional sentence, SOC, Survival, Survival rate, Chemoradiotherapy, Patient, Neoplasm, Tumor microenvironment, Standard of care, Doctor of Philosophy, Lymphocyte, Pancreatic cancer, Therapy, Cytokine, Injection, Pancreatitis, CD8, SITC, Recurrence, Valaciclovir, FDA, Annual general meeting, CADL, Food, Pharmaceutical industry

At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.

Key Points: 
  • At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.
  • Survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting.
  • “We are very encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data shown in this randomized clinical trial.
  • Only 1 out of 6 patients, randomized to control SoC chemotherapy, remained alive at data cut-off (alive at 50.6 months).

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Retrieved on: 
Friday, April 5, 2024
Research, FDA, Clinical Trials, Biometrics, Health, Pharmaceutical, General Health, Science, Oncology, Lung cancer, Chemoradiotherapy, CRT, Small-cell carcinoma, Radiation, AstraZeneca, Survival, NSCLC, Immunotherapy, Disease, Infection, Carcinoma, Incidence, Progression-free survival, Patient, Warning, Doctor of Philosophy, Prednisone, Adrenocorticotropic hormone, Creatinine, Prognosis, PFS, Recurrence, ACTH, Administration, Pneumonitis, SCLC, Vaccine

Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.

Key Points: 
  • Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.
  • Immune-mediated adrenal insufficiency occurred in 1.5% (6/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (0.3%) adverse reactions.

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Friday, March 15, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, MSD, OS, Chemoradiotherapy, CRT, Obstetrics, Congress, Gynaecology, CPS, Survival, Disease, Progression-free survival, Data monitoring committee, Cervical cancer, Patient, Neoplasm, Merck & Co., Overalls, Humanitas University, Bevacizumab, MRK, Cancer, ESMO, PFS, FIGO, PD-L1, Food, Pharmaceutical industry

At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.

Key Points: 
  • At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • Results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.
  • As previously reported , KEYNOTE-A18 met its other primary endpoint of progression-free survival (PFS) in 2023.

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Retrieved on: 
Monday, March 4, 2024
Head, Neck, Recurrence, Toxicity, Anemia, Completeness, Radiation, SPECT/CT, Chemoradiotherapy, EBRT, Macroglobulinemia, Lymphocytopenia, Thrombocytopenia, Patient, Neutropenia, Survival, Poster, Cytopenia, Cancer, Pharmaceutical industry

The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).

Key Points: 
  • The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).
  • The data were presented in a poster at the 2024 Multidisciplinary Head and Neck Cancers Symposium held February 29-March 2, 2024, in Phoenix, AZ.
  • Complete remission was achieved in 64% of patients, with an ORR of 73% (n=11).
  • Observed adverse events were consistent with the known toxicity profile of iopofosine I 131, with cytopenias being the most common with all patients recovering.

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Retrieved on: 
Monday, February 19, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, NSCLC, Fever, Progression-free survival, PFS, AstraZeneca, Heart, Periodic breathing, QT interval, MD, Chemoradiotherapy, Cough, Pemetrexed, Winship Cancer Institute, QT, OS, Electrolyte, Cardiomyopathy, Lung cancer, Safety, Emory University, CRT, LAURA, ILD, Patient, LVEF, Brain, Pharmaceutical industry

In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.

Key Points: 
  • In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.
  • Interstitial lung disease (ILD)/pneumonitis occurred in 4% of the 1813 TAGRISSO-treated patients; 0.4% of cases were fatal.
  • TAGRISSO is the only targeted therapy to improve patient outcomes in both early-stage disease in the ADAURA Phase III trial and late-stage disease in the FLAURA Phase III trial and FLAURA2 Phase III trial .
  • AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

BostonGene Announces Publication in Nature

Retrieved on: 
Friday, February 16, 2024
Research, Other Health, General Health, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Other Technology, Health, Other Science, Glioblastoma, Cancer, Recurrence, Doctor of Philosophy, MD, Immunotherapy, TME, Hospital, Clinical trial, RNA-Seq, Manuscript, GBM, Chemoradiotherapy, Lymphocyte, Virus, Patient, Survival, Get Behind Me Satan, Laboratory

BostonGene , a leading provider of AI-based molecular and immune profiling solutions, today announced the online publication of the manuscript “ Clinical trial links oncolytic immunoactivation to survival in glioblastoma ,” in Nature, an international journal publishing peer-reviewed research in all fields of science and technology prioritizing originality, significance, interdisciplinary relevance, timeliness, accessibility, sophistication, and groundbreaking findings.

Key Points: 
  • BostonGene , a leading provider of AI-based molecular and immune profiling solutions, today announced the online publication of the manuscript “ Clinical trial links oncolytic immunoactivation to survival in glioblastoma ,” in Nature, an international journal publishing peer-reviewed research in all fields of science and technology prioritizing originality, significance, interdisciplinary relevance, timeliness, accessibility, sophistication, and groundbreaking findings.
  • Utilization of immunotherapy for GBM has been challenging due to the scarcity of infiltrating antitumor lymphocytes caused by a highly immunosuppressive or “lymphocyte-depleted” tumor microenvironment (TME).
  • "BostonGene's innovative RNA-seq analytics lent novel insights into the dynamic changes associated with CAN-3110 therapy within the glioblastoma microenvironment," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.
  • “Looking to the future, we are excited at the possibilities of harnessing oncolytic viruses to transform immunosuppressive microenvironments across a range of solid cancer types.”

Cervical Cancer Studies Outline Innovative Treatment Options For Patients In 2024

Retrieved on: 
Thursday, February 15, 2024
Cervical cancer, Research, IIB, Disability, Chemoradiotherapy, CCRT, Social, Vaccination, Risk, Survival rate, Social Security, DFS, SSDI, Patient, Social Security Disability Insurance, Survival, Disease, HPV, Ageing, Cancer, Birth control

Research highlights the critical link between HPV (human papillomavirus) and cervical cancer, with the virus responsible for the majority of cases.

Key Points: 
  • Research highlights the critical link between HPV (human papillomavirus) and cervical cancer, with the virus responsible for the majority of cases.
  • Regular cervical cancer screening is essential for those aged 21 to 65, incorporating HPV testing followed by further assessments for those with positive results.
  • In evaluating treatment efficacy for stage IB2 to IIB cervical carcinoma, a 12-year study involving 626 patients compared neoadjuvant chemotherapy followed by surgery (NACT-S) with concomitant chemoradiotherapy (CCRT).
  • Cervical Cancer Awareness Month is a crucial time to raise public awareness about cervical cancer and the importance of early detection and treatment.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Friday, January 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC

Retrieved on: 
Monday, January 8, 2024
Roche, Lung cancer, DGX, Neoplasm, MRD, Research, Doctor of Philosophy, AFT, Chemoradiotherapy, Genentech, Quest Diagnostics, Patient, Safety, NSCLC, Hay, Pharmaceutical industry

BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT's interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable stage III non-small cell lung cancer (NSCLC).

Key Points: 
  • BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT's interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable stage III non-small cell lung cancer (NSCLC).
  • The AFT-57 clinical study is supported by Genentech, a member of the Roche Group, and will explore the efficacy and safety of an anti-PD-L1 atezolizumab (Tecentriq®) with or without tiragolumab (anti-TIGIT) in conjunction with chemoradiotherapy.
  • "Haystack MRD was purpose-built to detect ctDNA with unparalleled sensitivity, making it well-positioned to support the innovation of new treatment regimens."
  • "AFT is excited to work with Haystack Oncology to investigate promising new immunotherapy-based treatments in nationwide randomized cancer clinical trials," said David Kozono, MD, PhD, AFT Executive Officer and Alliance Immuno-Oncology Committee Co-Chair.